Fractyl Health Valuation

Is GUTS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GUTS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GUTS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GUTS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GUTS?

Key metric: As GUTS barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for GUTS. This is calculated by dividing GUTS's market cap by their current book value.
What is GUTS's PB Ratio?
PB Ratio	2.3x
Book	US$50.32m
Market Cap	US$124.58m

GUTS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1060.2x
Enterprise Value/EBITDA	-1.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does GUTS's PB Ratio compare to its peers?

The above table shows the PB ratio for GUTS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2x
ZOM Zomedica	0.6x	23.3%	US$125.1m
XAIR Beyond Air	1.4x	14.1%	US$36.6m
OBIO Orchestra BioMed Holdings	4.6x	3.2%	US$221.2m
HYPR Hyperfine	1.2x	6.9%	US$72.9m
GUTS Fractyl Health	2.3x	-57.3%	US$124.6m

Price-To-Book vs Peers: GUTS is expensive based on its Price-To-Book Ratio (2.3x) compared to the peer average (2x).

Price to Book Ratio vs Industry

How does GUTS's PB Ratio compare vs other companies in the US Medical Equipment Industry?

25 Companies	Price / Book	Estimated Growth	Market Cap
ADGM Adagio Medical Holdings	0.5x	n/a	US$35.90m
CODX Co-Diagnostics	0.4x	-8.3%	US$29.93m
RVP Retractable Technologies	0.2x	n/a	US$18.80m
HLTH Cue Health	0.06x	51.0%	US$14.72m

25 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: GUTS is good value based on its Price-To-Book Ratio (2.3x) compared to the US Medical Equipment industry average (2.6x).

Price to Book Ratio vs Fair Ratio

What is GUTS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GUTS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate GUTS's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GUTS forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$2.38	US$15.50 +551.3%	16.1%	US$18.00	US$13.00	n/a	2
Nov ’25	US$2.84	US$15.50 +445.8%	16.1%	US$18.00	US$13.00	n/a	2
Oct ’25	US$2.31	US$15.50 +572.5%	16.1%	US$18.00	US$13.00	n/a	2
Sep ’25	US$3.50	US$15.50 +342.9%	16.1%	US$18.00	US$13.00	n/a	2
Aug ’25	US$2.73	US$20.00 +632.6%	10.0%	US$22.00	US$18.00	n/a	2
Jul ’25	US$4.46	US$20.00 +348.4%	10.0%	US$22.00	US$18.00	n/a	2
Jun ’25	US$6.74	US$22.00 +226.4%	18.2%	US$26.00	US$18.00	n/a	2
May ’25	US$6.70	US$22.00 +228.4%	18.2%	US$26.00	US$18.00	n/a	2
Apr ’25	US$7.45	US$22.00 +195.3%	18.2%	US$26.00	US$18.00	n/a	2
Mar ’25	US$10.07	US$22.00 +118.5%	18.2%	US$26.00	US$18.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.